This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
type-2-diabetes
Type 2 Diabetes
Chronic metabolic disease from progressive insulin resistance and β-cell failure. Driven by obesity and inactivity. First-line: metformin (AMPK activation); GLP-1 agonists and SGLT2 inhibitors provide cardiovascular and renal benefit beyond glycemic control.
Entry Metadata
| Field | Value |
|---|---|
| ID | type-2-diabetes |
| Name | Type 2 Diabetes |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773-795. · PubMed 19336687
- Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-2128. · PubMed 26378978
- Marwick TH, Ritchie R, Shaw JE, Kaye D. Implications of Underlying Mechanisms for the Recognition and Management of Diabetic Cardiomyopathy. J Am Coll Cardiol. 2018;71(3):339-351. · PubMed 29348028